In its latest Horizon 10 perspective, Carbery highlights the increasing role of GLP-1 medications in the nutrition sector, urging the food ecosystem to respond with innovative product strategies. The company’s research and innovation program concludes that the “opportunity is immense for those who adopt.” News of Novo Nordisk’s new Wegovy pill launching early this year in the US is also fueling these advances. The company expects that the ingestible therapy will expand access for patients who may not have sought or accepted GLP-1 treatment before, and may improve affordability.
